TAK-041

CAS No. 1929519-13-0

TAK-041( NBI-1065846 )

Catalog No. M28601 CAS No. 1929519-13-0

TAK-041 is a potent and selective GPR139 agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 154 In Stock
5MG 140 In Stock
10MG 225 In Stock
25MG 452 In Stock
50MG 709 In Stock
100MG 1107 In Stock
200MG 1469 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAK-041
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK-041 is a potent and selective GPR139 agonist.
  • Description
    TAK-041 is a potent and selective GPR139 agonist.
  • In Vitro
    ——
  • In Vivo
    Animal Model:BALB/c mice Dosage:0.03, 0.3, and 3 mg/kg Administration:P.o.Result:Dose-dependently improved the social behavior of BALB/c mice.
  • Synonyms
    NBI-1065846
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    GPR
  • Recptor
    PDE5
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1929519-13-0
  • Formula Weight
    392.33
  • Molecular Formula
    C18H15F3N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (254.89 mM)
  • SMILES
    C[C@@H](c(cc1)ccc1OC(F)(F)F)NC(CN1N=Nc(cccc2)c2C1=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Wolf-Georg Forssmann, et al. Use of phosphodiesterase inhibitors in the treatment of prostatic diseases. US 8106061 B2
molnova catalog
related products
  • Ogremorphin

    Ogremorphin (GPR68-IN-1) is a potent inhibitor of GPR68 with an EC50 of 170 nM, used in the study of autoimmune chronic inflammatory diseases .

  • MS21570

    MS21570 as a GPR171 antagonist based on its ability to blockwith an?IC50?of 220 Nmthat reduces anxiety-like behavior and fear conditioning in mice.

  • Questiomycin A

    Questiomycin A is an antibiotic produced in crème fraiche with antibacterial and anticancer activities. Questiomycin A suppresses expression of GRP78, a cell-protective ER chaperone protein.